Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Thrombosis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Thrombosis
    Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review - (JAMA)
    Value of Genetic Testing for Preventing Blood Clots Unproven, Study Shows - (DGNews)
    Rivaroxaban More Effective Than Enoxaparin in Reducing Symptomatic Thrombotic Events in Patients Undergoing Total Hip or Knee Replacement: Presented at EHA - (DGDispatch)
    Use of MRI Increases Efficacy of Thrombolysis in Acute Stroke Beyond the 3.5-Hour Time Window: Presented at ESC - (DGDispatch)
    Thigh-Length Graduated Compression Stockings Do Not Significantly Prevent Thromboembolism After Stroke: Presented at ESC - (DGDispatch)

    News archive

     Recent webcasts/CME - Thrombosis
      Keys to Successful Outcomes from Anticoagulant and Antiplatelet Therapy: Addressing Medication Therapy Management Issues
      Thrombotic Thrombocytopenic Purpura: The Masquerader
      Cardiovascular Series: Guidelines for Anticoagulant Therapy in the Prevention and Treatment of Venous Thromboembolism: Achieving Meaningful Quality Improvement
      Perioperative Management Strategies for the Patient Requiring Warfarin
      VTE and the Hospital Pharmacist: Implementing Optimal Management Protocols

      Webcasts/CME archive

       Recent cases - Thrombosis
        Clopidogrel Resistance "Live" - The Risk of Stent Thrombosis Should Be Evaluated Before Procedures
        Stent Angioplasty of Narrowed Portocaval Shunt in Budd Chiari Syndrome: A Case Report
        Refractory Thrombotic Thrombocytopenic Purpura Associated with Oral Contraceptives and Factor V Leiden: A Case Report
        Contrast Echocardiography for the Evaluation of Tumors and Thrombi
        Hybrid Epicardial and Endocardial Catheter Ablation in a Patient With Atrial Fibrillation and Suspicious Left Atrial Thrombus

        Cases archive
          




        my personal edition > thrombosis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Prophylaxis And Screening Recommended For Pregnant Women At High Risk Of Venous Thromboembolism

        A DGReview of :"Prediction, prevention, and treatment of venous thromboembolic disease in pregnancy"
        Seminars in Thrombosis and Hemostasis

        05/15/2003
        By Deanna M. Green


        Prophylactic treatment and genetic screening are recommended for women with a higher risk of venous thromboembolism (VTE) during pregnancy and the puerperium, according to a review by Dr. RB Zotz and colleagues from Düsseldorf, Germany.

        Pregnancy is both an acquired and independent risk factor for VTE, and it is the primary cause of morbidity and mortality during pregnancy and the puerperium. Normal physiological changes in blood coagulation and fibrinolysis factors are required to prepare the body for the hemostatic stress of labor, but these changes can lead to VTE in high-risk women.

        It is therefore important for physicians to assess the individual thrombotic risk during pregnancy based on known risk factors. Furthermore, it is necessary to develop a prophylactic protocol based on risk stratification to help prevent VTE during pregnancy.

        Acquired risk factors for VTE during or after pregnancy include maternal age over 35 years, weight over 80 kg, 4 or more pregnancies, cesarean section, oral contraception use, and personal or family history of VTE.

        Women with severe deficiencies in coagulation factors such as antithrombin or protein C have an intermediate to high risk of VTE and should receive heparin prophylaxis during pregnancy.

        Furthermore, women who are carriers of mutations in either Factor V Leiden or prothrombin have about a 1 in 25 chance of thrombosis during pregnancy and the puerperium. Heparin prophylaxis is recommended for these women throughout the gestational period, or at least in the postpartum period.

        Due to the low risk of VTE observed in women without prior thrombosis, routine screening of all pregnant women for congenital thrombophilia is not currently recommended. However, thrombophilia screening is recommended for women with a personal or family history of VTE.
        Semin Thromb Hemost 2003 April;29:2:143-154. "Prediction, prevention, and treatment of venous thromboembolic disease in pregnancy"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send